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Poster Session I S209chemotherapy with rituximab, carmustine, etoposide, cytarabine and
melphalan. Adjuvant immunotherapy consisted of rituximab
375 mg/M2 IV weekly and sargramostim 250 ug s.c. TIW during
weeks 5 to 8 and 24 to 27 post transplant.
Results: Seven patients had successful mobilization (mean CD34/kg
collected 12.5E6 and infused 9E6) and underwent transplant. Me-
dian time to neutrophil and platelet engraftment was 9 and 10 days
respectively. Six patients are alive with no evidence of disease from
3 to 18 months post transplant. One patient relapsed at 11 months.
4/4 patients receiving at least once cycle of adjuvant immunotherapy
developed grade 1 to 4 neutropenia from 3 to 34 weeks post adjuvant
rituximab. Neutrophil counts recovered following treatment with
G-CSF, but recurred in all 4 patients without additional exposure
to rituximab. One patient who had engrafted platelets developed
grade 2 thrombocytopenia on day 33 post transplant. Platelets spon-
taneously recovered.
Conclusions: Delayed-onset neutropenia is a known complication
of rituximab. The incidence may be higher when rituximab is used
following ASCT. It is not clear if the timing of rituximab administra-
tion post transplant or the concomitant use of sargramostim contrib-
uted to the high incidence of delayed neutropenia in this study.
Larger studies and longer followup will be needed to determine if ad-
juvant immunotherapy decreases relapse.137
CONSOLIDATION THERAPY FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR NON-HODGKINS AND HODGKINS LYMPHOMAS
Colvin, G.A., Milani, C., Berz, D., Quesenberry, P. Brown University,
Providence, RI
Purpose: To determine whether autologous stem-cell transplanta-
tion (ASCT) followed by consolidation with Rituximab or irradia-
tion is superior to ASCT alone in adults with advanced or relapsed
lymphoma.
Patients and Methods: Fourteen consecutive lymphoma patients
were entered onto this prospective, single center, phase II study. Sev-
enteen previously transplanted patients were used as historical con-
trols with continuous follow-up. Patients with non-Hodgkin’s
lymphoma (NHL, n5 11) or Hodgkin’s disease (HD, n5 3) re-
ceived ASCT followed by consolidation with Rituximab (375 mg/
m2/week x4, every 6 months x5) or irradiation (20-30 Gy) respec-
tively.
Results: Age, diagnosis (NHL vs. HD), B symptoms, risk factors,
LDH, previous treatment response and histological type were well
balanced between the two groups. With a median follow-up of
21.3 months, the 30-month relapse rate was 23% and 53%
(P5 0.045), disease-free survival was 70% and 41% (P5 0.03) and
overall survival was 73% and 47% (P5 0.07) for the consolidation
group and historical controls, respectively. A multivariate analysis
showed that age$ 55 and abnormal pre-transplant LDH were pre-
dictors of poor outcome. When NHL patients were analyzed sepa-
rately (n5 24), 30-month relapse rate was 27% and 63%
(P5 0.08), disease free survival was 73% and 47% (P5 0.05) and
overall survival was 70% and 40% (P5 0.06) for consolidation and
control arms, respectively.
Conclusion: The use of ASCT followed by consolidation using Rit-
uximab (NHL) or irradiation (HD) in adults with advanced lym-
phoma showed a markedly decreased relapse rate and improved
disease free and overall survival compared with conventional
ASCT. The NHL subgroup (Rituximab) also demonstrated that
consolidation produced a marked advantage.138
COMBINED AMIFOSTINE AND CRYOTHERAPY FOR PREVENTION OF
ORAL MUCOSITIS (OM) FOLLOWING HIGH DOSE CHEMOTHERAPY
WITH MELPHALAN AND AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANT (HCT) FOR MULTIPLE MYELOMA (MM)
Lopez-Bover, M., Thompson, M., Santos, V., Holder, M., Feinstein, L.,
Grosman, D. Memorial Cancer Institute, Pembroke Pines, FLOM is a major cause of morbidity following autologous HCT
for MM. Amifostine is a free radical scavenger that reduces proin-
flammatory cytokine production. Cryotherapy causes vasoconstric-
tion of vessels in the oral cavity. Randomized controlled trials
have demonstrated a significant reduction in the severity and du-
ration of OM when amifostine or cryotherapy is administered
with high dose melphalan prior autologous HCT for MM. To
date, no report has been made of outcomes when both treatments
are used concurrently.
We performed 28 autologous HCTs on 21 patients with MM
in an outpatient setting. Patients received amifostine 740 mg/m2
24 hours prior to and immediately prior to melphalan (200 mg/
m2 for 19 patients and 140 mg/m2 for 2 patients; dose depen-
dent on renal function). Cryotherapy was administered for four
hours beginning 30 minutes prior to the administration of mel-
phalan. Six patients had a decline in systolic blood pressure
of$ 20% of baseline following the administration of amifostine.
Aggressive intravenous hydration and Trendeleberg positioning
resulted in the rapid return to baseline blood pressure in all
cases. Prehydration and holding antihypertensive medications
for 24 hours prior to the first dose of amifostine reduced symp-
tomatic hypotension.
No patient was admitted for OM. The one patient who required
both total parenteral nutrition and narcotic analgesics for grade III
OM did not remove his dentures during cryotherapy. One patient
experienced grade II OM that was managed with oral narcotic anal-
gesics. The remaining 19 patients experiencing either grade I (n5 1)
or no (n5 18) OM. Combined amifostine and cryotherapy is a well-
tolerated and effective method of reducing OM following high dose
melphalan and autologous HCT for MM.139
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RE-
FRACTORY OR RELAPSED HODGKIN DISEASE IN COLOMBIA
Linares, A.1,2, Abello, V.1, Pedraza, E.1, Rosales, C.1, Rosales, M.1,
Esguerra, H.1, Figueroa, J.1, Rubio, A.2 1Clınica de Marly, Bogota, Co-
lombia; 2Universidad Nacional de Colombia, Bogota, Colombia
Objectives: The aim of this study is to report outcomes of patients
with Hodgkin Disease (HD) after high dose therapy and autologous
Hematopoietic Stem Cell Transplantation (auto-HSCT) in a single
center in Colombia.
Methods: One hundred four patients with relapsed or refractory
HD were treated with auto-HSCT between 1994 and 2008. Clinical
status previous to transplantation, and events as relapse or death were
analyzed to establish 5 year Overall Survival (OS) and Event Free
Survival (EFS).
Results: One hundred four patients have had 105 procedures (one
patient with 2 auto-SCT). Thirty-five female and 69 male, 79 adults
and 25 less than 16 years, with average age of 27.4 years (range 5 to 66
yrs). Forty-one patients (39,4%) with refractory disease, 21 with
early relapse (20%) and 42 with late relapse (40,4%).
Clinical stage at diagnosis: I and IIA 24 patients (23%), IIB 28 pa-
tients (26.9%), IIIA 7 patients (6.7%), III B 21 patients (20%), stage
IV 21 patients (20%) and (3 patients unknown). The source of cells
was peripheral blood in 95 transplants (91.4%), bone marrow in 6
(5.7%) and combined in 2 procedures (1.9%) combined, (2 patients
unknown).
The conditioning chemotherapy was BEAM in 56 transplants
(53.3%), cyclophosphamyde-etoposide-melphalan in 26 (24.7%)
and other protocols in 23 (21.9%) transplants. At the time of trans-
plantation, 61 patients (58%) were in complete remission, 36 (34%)
in partial remission and 5 (4.7%) with active disease.
Twenty nine patients had relapse, of them 11 are dead. Seven
patients had non relapse mortality: 5 with infectious complications,
1 with colecistitis and 1 with graft failure. Two patients died for
complications of a second neoplasm. The mortality in the first
100-days was 3% (3 patients with infectious complications).
With a median of 971 days of follow-up (range 12 to 5587
days), 59 (56.7%) patients are in complete remission, 17 (16.3%)
are alive after relapse, 21 (20.1%) have died and 7 (6.7%) were
lost for follow-up.
